Kerri Fitzgerald

DocwireNews

Revlimid&reg; (lenalidomide) significantly delayed disease progression in patients with smoldering <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-grants-rmat-designation-for-car-t-cell-therapy-for-multiple-myeloma/">multiple myeloma</a> (SMM), according to a study published in the Journal of Clinical Oncology.The current standard of care for SMM is observation without therapy; however, the researchers said the findings support &ldquo;early intervention&rdquo; with lenalidomide in this patient cohort, changing the standard of care.This large randomized clinical trial assessed the efficacy of single-agent lenalidomide versus observation in 182 patients with intermediate- or high-risk <a href="https://www.docwirenews.com/conference-coverage/imw/clinical-and-biological-early-relapse-predictors-in-multiple-myeloma-an-analysis-from-the-mmrf-commpass-study/">SMM</a>. Patients received lenalidomide 25 mg orally on days one to 21 of a 28-day cycle (n=92) or observation (n=90).<h2>Delayed disease progression with lenalidomide</h2>After a median follow-up of 35 months, treatment response was 50% in the lenalidomide cohort (95% CI, 39-61), and there were zero responses in the observation arm. Progression-free survival (PFS; primary endpoint) was significantly longer with lenalidomide (hazard ratio [HR] = 0.28; 95% CI, 0.12-0.62;&nbsp;P=0.002). One-, two-, and three-year PFS was 98%, 93%, and 91% in the lenalidomide group versus 89%, 76%, and 66% in the observation arm, respectively.Six deaths occurred: two in the lenalidomide arm and four in the observation arm (HR=0.46; 95% CI, 0.08-2.53). Grade 3/4 non-hematologic adverse events occurred in 25 patients (28%) receiving lenalidomide.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Does Revlimid® Warrant a Change in Standard of Care for Smoldering Multiple Myeloma

Oncology

Revlimid® (lenalidomide) significantly delayed disease progression in patients with smoldering multiple myeloma (SMM), according to a study published in the Journal of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe